Intraocular Melanoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Intraocular Melanoma Market is segmented By Site (Sclera, Retina, Uvea), By Diagnosis (Eye Exam, Imaging, Biopsy), By Therapy (Radiation Therapy, Laser Therapy, Surgery, Targeted therapy, Chemotherapy), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Intraocular Melanoma Market Overview

The Global Intraocular Melanoma Market is expected to grow at a high CAGR during the forecast period (2024-2031).

Intraocular melanoma is rare cancer that develops inside the eye. It creates melanocytes (cells that generate pigment or color) to grow out of control. The disorder can lead to vision changes or loss. Intraocular melanoma usually attacks the middle part of the eye called the uvea. The uvea is among the sclera (outer white part of the eye), including the retina (inner part of the eye that processes light and controls vision).

Vision loss is expected with intraocular melanoma. The amount of vision loss depends on the size of the melanoma. Long-standing eye melanomas may cause comprehensive loss of vision. Intraocular melanoma is the most common type of eye cancer in adults. But the condition is infrequent. Healthcare providers diagnose about 2,500 people in the U.S. with intraocular melanoma each year.

The cause of intraocular melanoma is unclear, but UV light is a risk factor. However, many new treatments such as pharmacotherapy have increased the treatment options with the high risk of infection recurrence among patients.

Intraocular Melanoma Market Scope

For more Insights - Request Free Sample

Intraocular Melanoma Market Dynamics

The intraocular melanoma market growth is driven by the increasing development of innovative treatment options in intraocular melanoma treatment are expected to drive the growth of the global intraocular melanoma market during the forecast period.

Innovative treatment options in intraocular melanoma treatments will drive the market growth

Advancements in growing innovative treatment options in intraocular melanoma therapies such as understanding the molecular features of the intraocular tumor into genetic alternations and mutations studies in patients and novel treatments based on inhibition mechanism of interpretation of growth factor receptors such as c-Met and c-Kit are being investigated to deliver better treatment options for patients.

Moreover, rampant research about melanoma, increasing incidence burden of intraocular melanoma, and developing several clinical trials for new methods, in turn, is expected to support the growth of the intraocular melanoma market over the forecasted period. For instance, as per the American Society of Clinical Oncology, in 2015, around 3,540 adults (2,130 men and 1,410 women) in the U.S. were diagnosed with primary intraocular cancer. According to the American Academy of Ophthalmology (AAO), 2014 data findings, uveal melanoma is the most generally diagnosed primary intraocular malignancy in adults, with 90% of uveal melanoma including the choroid 5% affecting the ciliary body, and 5% developing in the iris. Additionally, intraocular melanoma is  5%-10% of all melanomas. Additionally, according to the American Academy of Ophthalmology (AAO), 2014 data findings, the incidence of intraocular melanoma is more eminent among the fairly pigmented groups while exceedingly lower among the Asian and African populations.

Rapid research and development activities associated with melanomac is driving the market growth

Rapid research and development activities associated with melanoma, coupled with the increasing burden of intraocular melanoma, and an increasing number of clinical trials for new treatments, are expected to drive the growth of the global intraocular melanoma treatment market shortly. The prevalence of eye cancer has increased by 25% in the U.K. Additionally, rising healthcare expenditures and increasing research and development investments by the market's significant players boost the market growth.

Side effects associated with certain medications coupled with the high cost of cancer treatment

High cost and adverse side effects associated with the treatment of intraocular melanoma coupled with poor reimbursement infrastructure are expected to hamper the growth of the intraocular melanoma market in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had an unprecedented impact on the National Health Service in the United Kingdom. The UK Ocular Oncology Services evaluated the impact on intraocular melanoma care in the UK. All four adult Ocular Oncology centers participated in a multicentre retrospective review comparing uveal melanoma referral patterns and treatments in 4 months during the national lockdown and first wave of the COVID-19 pandemic in 2020 with corresponding periods in the previous two years. During the national lockdown, referral numbers and confirmed intraocular melanoma cases reduced considerably, equalling 120 fewer diagnosed uveal melanoma cases than the previous two years. As the COVID-19 pandemic continues to mount pressure and reveal its hidden impact on the intraocular melanoma market in the forecast period.

Intraocular Melanoma Market Segment Analysis

By diagnosis, the intraocular melanoma market is classified into eye exam, imaging, biopsy.

The biopsy segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)   

A biopsy is a method to remove a piece of tissue or a unit of cells of the body to be examined in a laboratory. If a patient is experiencing specific symptoms doctor has identified an area of concern, it may undergo a biopsy to determine whether the patient has cancer or some other condition. Biopsies are most usually done to examine for cancer. But biopsies can help recognize many other conditions. In some cases, a biopsy of normal-appearing tissue may be done. A biopsy can help check for eye cancer spread or denial of a transplanted organ. There are various kinds of biopsies. Approximately all of them involve using a sharp tool to remove a small amount of tissue.

More invasive biopsies may be done in a hospital, a surgery centre, or a specialized doctor's office. You would make a separate appointment for the biopsy. In most cases, sedating and pain relief medicines are given, reducing any discomfort. You likely won't be able to drive after receiving these medicines. Sometimes, a biopsy may be useful to check for certain gene mutations (changes) that can predict outcomes (prognosis) as well as help choose targeted drugs for eye cancer. Also, certain eye melanomas can spread for many years before they are diagnosed so doing a biopsy of a worrisome area early may be helpful.

Based on therapy, the intraocular melanoma market is classified into targeted therapy radiation therapy, immunotherapy, chemotherapy.

The chemotherapy segment is expected to dominate the Intraocular Melanoma market during the forecast period  

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Intraocular Melanoma Market Geographical Share

North America region holds the largest market share in the global Intraocular Melanoma market

North America region is dominating the global intraocular melanoma market accounted for the largest market share in 2020, owing to the increasing incidence of intraocular melanoma in the region. For instance, as per the National Cancer Institute data in 2016, the mean age-adjusted percentage of intraocular melanoma in the U.S. is around 4.3-8.4 new cases per million people per year.

Several research organizations in the countries are engaged in raising funding for a study to develop intraocular melanoma therapy. For instance, the Melanoma Research Foundation, a Washington-based organization assigned to receive adequate treatment in various types of melanoma, raised around US$ 1.2 million for intraocular melanoma and its treatment from 2012. Furthermore, in April 2018, the Ocular Melanoma Foundation, in collaboration with the American Association for Cancer Research, offered research funding of US$ 150,000 to researchers at the Casey Eye Institute to study advertising hybrid tumor cells as a prognostic biomarker for intraocular melanoma.

Intraocular Melanoma Market Companies and Competitive Landscape

The intraocular melanoma market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Astra Zeneca plc, Eli Lilly & Co., Pfizer, Inc. Novartis AG, and Spectrum Pharmaceuticals, Inc., Merck, Roche, Amgen, Bayer, and Spectrum Pharmaceuticals, Inc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Intraocular Melanoma market globally.    

Pfizer Inc. 

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others. 

Why Purchase the Report?

• Visualize the composition of the intraocular melanoma market segmentation by site, therapy, diagnosis, and end-user highlighting the key commercial assets and players.
• Identify commercial opportunities in the intraocular melanoma market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of intraocular melanoma market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global intraocular melanoma market report would provide access to an approx. 51 market data table, 61 figures and 180 pages.  

Target Audience

• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
• Manufacturers